JO
TRVI icon

John Overdeck’s Trevi Therapeutics TRVI Stock Holding History

John Overdeck’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,415
Closed -$458K – 5440
2026
Q1 		$458K Sell
38,415
-45,340
-54% -$508K ﹤0.01% 3788
2025
Q4 		$1.05M Sell
83,755
-36,175
-30% -$418K ﹤0.01% 2880
2025
Q3 		$1.1M Sell
119,930
-310
-0.3% -$2.33K ﹤0.01% 2516
2025
Q2 		$658K Buy
120,240
+2,504
+2% +$15.6K ﹤0.01% 2462
2025
Q1 		$741K Sell
117,736
-18,071
-13% -$86.2K ﹤0.01% 2334
2024
Q4 		$560K Buy
+135,807
New +$435K ﹤0.01% 2482
2023
Q2 		– Sell
-12,928
Closed -$23.9K – 3263
2023
Q1 		$23.9K Sell
12,928
-15,725
-55% -$35.6K ﹤0.01% 2836
2022
Q4 		$55.3K Sell
28,653
-50,784
-64% -$100K ﹤0.01% 2579
2022
Q3 		$122K Buy
+79,437
New +$260K ﹤0.01% 2200

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

John Overdeck's TRVI Position: Q2 2026 in Review

John Overdeck sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 38,415 shares — an estimated $458K sold.

John Overdeck first reported a position in TRVI in Q3 2022 and held it in 9 quarters. The position peaked at $1.1M in Q3 2025. 216 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • John Overdeck reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 38,415 Trevi Therapeutics shares in Q2 2026, an estimated $458K.
  • John Overdeck first reported a position in Trevi Therapeutics in Q3 2022 and held it in 9 quarters.
  • John Overdeck's Trevi Therapeutics position peaked at $1.1M in Q3 2025.
  • 216 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.